Out-licensing
Up-to-date access to technology licensing opportunities worldwide.
- Out-licensing
- Browse
Licensing opportunities
The unique ORS effervescent tablet has been developed according to the latest guidelines of the WHO. It has a substantial marketshare in several countries. We are looking for partners to further expand this success. More
Supercritical fluid crystal and particle engineering to form particles with strong aerodynamic performance and exceptional size uniformity for optimised pulmonary/nasal delivery More
Related Reports
Market Research Reports provided by reports.iptechex.com
Jan 2011 - 124 pages - $1,740
Jun 2009 - 118 pages - $1,040
Nov 2009 - 830 pages - $1,040
Jun 2009 - 110 pages - $1,040
Nov 2010 - 428 pages - $2,695
Aug 2008 - 120 pages - $1,040
Jun 2009 - 472 pages - $3,140
Jun 2008 - 175 pages - $3,835
Oct 2010 - 97 pages - $3,835
Oct 2009 - 192 pages - $3,500
Your selection
Browse By
- Industry sector
- Intravesical
- Nasal
- Nasal topical
- Ophthalmic
- Oral liquid
- Oral solid
- Otic
- Parenteral
- Pulmonary
- Rectal
- Systemic
- Topical
- Vaginal
- Therapeutic target
- Acute coronary syndromes
- Anemia
- Anticoagulants
- Blood clotting
- Blood composition
- Cardiovascular disorder (other)
- Cerebrovascular disorders
- Thrombotic disorders
- Treatments
- Vascular
© Copyright 1998-2013 IP Technology Exchange, Inc All rights reserved. Terms and Conditions | Contact us